Home
ZymoGenetics

ZymoGenetics Market Share Analysis for November 2025

Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.

Health > Biotechnology and Pharmaceuticals

Domainzymogenetics.com

Year Founded--

Employees201 - 500

Annual Revenue$75M - $100M

ZymoGenetics

ZymoGenetics (including company regionals)

zymogenetics.com

See more website traffic and engagement information

ZymoGenetics Revenue up to November 2025 is 75M - 100M

revenue generated by ZymoGenetics top domains

ZymoGenetics top domains revenue over 3 years

Revenue for ZymoGenetics top domains

zymogenetics.com75M - 100M

See more with Sales Intelligence

Total visits to ZymoGenetics's top domains

Understand ZymoGenetics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in ZymoGenetics's top domains

Analyze ZymoGenetics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on ZymoGenetics's top domains

See how ZymoGenetics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

ZymoGenetics top competitors by domain

Top similar sites in November 2025, ranked by their affinity

optimerpharma.comCompany NameOptimer PharmaceuticalsEmployees201 - 500HQUnited States, New Jersey, Jersey CityAnnual revenue$75M - $100MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by ZymoGenetics

These are the website technologies, by industry, used by ZymoGenetics top domains

Conversion & Analytics (2)

Omniture

Mobile (1)

Meta Viewport

Recruitment (1)

Taleo

Social (1)

Facebook Social Plugins

More Technologies

1

See all

News & Signals from ZymoGenetics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsWilliams leaves ZymoGenetics as Chief Executive Officer and member of the Board of Directors.Dr. Williams joined Biogen from ZymoGenetics, where he was Chief Executive Officer and member of the Board of Directors.

NewsZymoGenetics sold assets to Merck KGaA on Jan 1st '08.Merck acquired exclusive worldwide development and commercialization rights for atacicept from Zymogenetics in 2008 (Zymogenetics was acquired by Bristol-Myers Squibb in 2010).

NewsBristol-Myers Squibb Co acquired ZymoGenetics for $985M on Jan 1st '10.Zymogenetics was founded in 1981 in Seattle and was acquired by Bristol-Myers Squibb in 2010 for $885 million.